Study summary · research use only
Kisspeptin signalling in the physiology and pathophysiology of the urogenital system
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses kisspeptin, a peptide hormone signaling via the kisspeptin receptor (KISS1R), and its reported roles in the urogenital system. The abstract describes involvement of kisspeptin-KISS1R signaling in ovarian function, including oocyte development, and in male reproductive functions such as spermatogenesis and sperm capacitation. It also reports involvement in kidney physiology, citing preclinical animal models in which kisspeptin and/or KISS1R expression was altered in chronically impaired kidneys. The review further reports that kisspeptin suppresses metastasis of urogenital carcinomas, and that tissue- and tumor-stage-specific changes in kisspeptin and KISS1/KISS1R expression have been suggested as possible biomarkers for diagnosis and prognosis of urogenital carcinomas. Species not specified.
Abstract
Kisspeptin is a peptide hormone, which signals via the G-protein-coupled kisspeptin receptor (KISS1R). Kisspeptin-KISS1R signalling has been implicated in various physiological and pathophysiological processes in the urogenital system, including critical roles in ovarian function as a key player in the regulation of oocyte development. Kisspeptin also has roles in several different functions of the male reproductive tract, such as spermatogenesis and sperm capacitation, and is also thought to be involved in kidney physiology - studies in preclinical animal models have reported that expression of kisspeptin and/or KISS1R is altered in chronically impaired kidneys. The wider importance of kisspeptin action in the urogenital tract has been highlighted by the finding that it suppresses metastasis of urogenital carcinomas; besides the possible therapeutic potential of this finding, tissue and tumour-stage-specific alterations in kisspeptin and KISS1/KISS1R expression could potentially be used as biomarkers for the diagnosis and prognosis of urogenital carcinomas.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.